Big Pharma pours billions into China biotech, deepening US tech rivalry

Major pharmaceutical companies are investing billions in Chinese biotechnology firms, signaling a strategic shift in global R&D and manufacturing. This deepens the US-China technology competition, as biotech joins AI as a contested frontier. The scale and specific deals remain undisclosed, but the trend underscores China's rising biotech capabilities and Western dependence on its ecosystem.